State of Alaska Department of Revenue’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.13M | Buy |
13,303
+958
| +8% | +$68.8K | 0.01% | 982 |
|
|
2026
Q1 | $813K | Buy |
12,345
+400
| +3% | +$25.4K | 0.01% | 1179 |
|
|
2025
Q4 | $758K | Sell |
11,945
-835
| -7% | -$51.9K | 0.01% | 1238 |
|
|
2025
Q3 | $702K | Sell |
12,780
-675
| -5% | -$27.8K | 0.01% | 1258 |
|
|
2025
Q2 | $444K | Sell |
13,455
-365
| -3% | -$12.7K | ﹤0.01% | 1409 |
|
|
2025
Q1 | $555K | Buy |
13,820
+365
| +3% | +$16.8K | 0.01% | 1313 |
|
|
2024
Q4 | $632K | Buy |
13,455
+65
| +0.5% | +$3.38K | 0.01% | 1293 |
|
|
2024
Q3 | $706K | Buy |
13,390
+925
| +7% | +$51.6K | 0.01% | 1243 |
|
|
2024
Q2 | $675K | Buy |
12,465
+1,830
| +17% | +$110K | 0.01% | 1221 |
|
|
2024
Q1 | $745K | Sell |
10,635
-49,687
| -82% | -$3.84M | 0.01% | 1198 |
|
|
2023
Q4 | $5.04M | Buy |
60,322
+517
| +0.9% | +$18.7K | 0.06% | 357 |
|
|
2023
Q3 | $1.76M | Sell |
59,805
-3,158
| -5% | -$105K | 0.02% | 683 |
|
|
2023
Q2 | $2.05M | Sell |
62,963
-1,839
| -3% | -$68K | 0.02% | 648 |
|
|
2023
Q1 | $2.28M | Sell |
64,802
-1,092
| -2% | -$44.5K | 0.03% | 597 |
|
|
2022
Q4 | $3.02M | Buy |
65,894
+667
| +1% | +$28.7K | 0.04% | 493 |
|
|
2022
Q3 | $3.16M | Buy |
65,227
+437
| +0.7% | +$21K | 0.04% | 449 |
|
|
2022
Q2 | $2.54M | Buy |
64,790
+6,270
| +11% | +$252K | 0.03% | 541 |
|
|
2022
Q1 | $2.15M | Sell |
58,520
-870
| -1% | -$30.9K | 0.02% | 647 |
|
|
2021
Q4 | $2.71M | Sell |
59,390
-1,530
| -3% | -$59K | 0.03% | 582 |
|
|
2021
Q3 | $2.18M | Buy |
60,920
+11,275
| +23% | +$332K | 0.02% | 673 |
|
|
2021
Q2 | $982K | Buy |
49,645
+1,675
| +3% | +$39.3K | 0.01% | 1103 |
|
|
2021
Q1 | $1.11M | Sell |
47,970
-7,120
| -13% | -$152K | 0.01% | 988 |
|
|
2020
Q4 | $1.14M | Sell |
55,090
-10,630
| -16% | -$194K | 0.01% | 889 |
|
|
2020
Q3 | $1.42M | Buy |
65,720
+9,620
| +17% | +$225K | 0.02% | 710 |
|
|
2020
Q2 | $1.32M | Buy |
56,100
+1,290
| +2% | +$24.2K | 0.02% | 734 |
|
|
2020
Q1 | $646K | Buy |
54,810
+10,200
| +23% | +$130K | 0.01% | 976 |
|
|
2019
Q4 | $473K | Sell |
44,610
-465
| -1% | -$4.78K | 0.01% | 1328 |
|
|
2019
Q3 | $512K | Buy |
45,075
+25,467
| +130% | +$320K | 0.01% | 1264 |
|
|
2019
Q2 | $220K | Buy |
19,608
+1,170
| +6% | +$11.3K | ﹤0.01% | 1426 |
|
|
2019
Q1 | $149K | Buy |
18,438
+205
| +1% | +$1.51K | ﹤0.01% | 1530 |
|
|
2018
Q4 | $115K | Buy |
18,233
+1,564
| +9% | +$11.5K | ﹤0.01% | 1559 |
|
|
2018
Q3 | $164K | Buy |
16,669
+320
| +2% | +$2.57K | ﹤0.01% | 1543 |
|
|
2018
Q2 | $135K | Hold |
16,349
| – | – | ﹤0.01% | 1558 |
|
|
2018
Q1 | $117K | Buy |
16,349
+6,230
| +62% | +$53.4K | ﹤0.01% | 1542 |
|
|
2017
Q4 | $82K | Hold |
10,119
| – | – | ﹤0.01% | 1552 |
|
|
2017
Q3 | $146K | Buy |
10,119
+1,070
| +12% | +$14.6K | 0.01% | 1099 |
|
|
2017
Q2 | $109K | Buy |
+9,049
| New | +$126K | 0.01% | 1089 |
|
Other funds holding CYTK
State of Alaska Department of Revenue's CYTK Position: Q2 2026 in Review
State of Alaska Department of Revenue increased its Cytokinetics (CYTK) stake by 7.8% in Q2 2026, buying an estimated $68.8K and bringing the position to 13,303 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #982.
State of Alaska Department of Revenue first reported a position in CYTK in Q2 2017 and has held it in 37 quarters since. The position peaked at $5.04M in Q4 2023. 272 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- State of Alaska Department of Revenue held 13,303 shares of Cytokinetics worth $1.13M as of Q2 2026.
- State of Alaska Department of Revenue bought 958 Cytokinetics shares in Q2 2026, an estimated $68.8K.
- Cytokinetics made up 0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #982 holding.
- State of Alaska Department of Revenue first reported a position in Cytokinetics in Q2 2017 and has held it in 37 quarters since.
- State of Alaska Department of Revenue's Cytokinetics position peaked at $5.04M in Q4 2023.
- 272 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.